Cell line · CVCL_1870
Papers33
1 to 20 of 33
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Genetically distinct microenvironment determines cancer survival and response to therapy in mice. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Epigenetic activation of EBV BGLF4 determines antiviral-based regimen response in EBV+CNS lymphoproliferative disease. | Blood Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Evaluation of the Role of AID-Induced Mutagenesis in Resistance to B-Cell Receptor Pathway Inhibitors in Chronic Lymphocytic Leukemia. | Curr Issues Mol Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DUSP11 is an Intracellular Innate Immune Checkpoint in Lung Adenocarcinoma. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Dynamic stimulation promotes functional tissue-like organization of a 3D human lymphoid microenvironment model in vitro. | Cell Rep Methods | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. | Blood Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2-Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Stromal cells support the survival of human primary chronic lymphocytic leukemia (CLL) cells through Lyn-driven extracellular vesicles. | Front Med (Lausanne) | 2022 | Its Methods give the RRID and name the line | PubMed | |
| The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia. | Blood Adv | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Loss of synergistic transcriptional feedback loops drives diverse B-cell cancers. | EBioMedicine | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia. | Nat Commun | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Discovery of Candidate DNA Methylation Cancer Driver Genes. | Cancer Discov | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia. | J Exp Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| The LL-100 panel: 100 cell lines for blood cancer studies. | Sci Rep | 2019 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1870/papers